Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.
Volume
42
Pagination
tps8124 - tps8124
Publisher
DOI
10.1200/jco.2024.42.16_suppl.tps8124
Journal
Journal of Clinical Oncology
Issue
ISSN
0732-183X